Absci Corporation (ABSI) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-24
Business type: Asset play
How it makes money
It generates revenue from drug creation fees and milestones, with three partners accounting for 95% of partner program revenue in 2025.
The company earns revenue by performing drug discovery for partners like Merck and AstraZeneca using its generative AI models and wet-lab validation. Revenue was $2.8 million in 2025, driven by upfront fees and the achievement of technical milestones rather than product sales.
Profitability depends on advancing internal candidates like ABS-201 and successfully converting discovery partnerships into long-term licenses. These licenses would potentially provide downstream royalties and commercial milestone payments as drug candidates reach the market.
What protects it: the moat
Its Origin-1 model designs full-length monoclonal antibodies for zero-prior epitopes that lack previously solved structures for protein binders.
The company maintains a competitive advantage through its Origin-1 generative engine, which management claims is the first to design antibodies against epitopes that have no known binding protein. This capability allows it to address "hard-to-drug" targets that traditional discovery methods cannot reach.
Its 77,000+ square foot "lab-in-the-loop" facility generates proprietary high-throughput data to refine these models. Origin-1 has been validated against four targets, demonstrating functional potency and atomic accuracy confirmed by cryogenic electron microscopy.
What growth costs
It invests $15 million per program to advance candidates to IND stage, utilizing a 77,974 square foot facility for its lab-in-the-loop operations.
The company's primary reinvestment goes toward R&D, which reached $81.4 million in 2025. This funding supports the advancement of its internal pipeline, including the HEADLINE Phase 1/2a trial for ABS-201 and early-stage oncology assets.
Management states it can reach Investigational New Drug (IND) status for roughly $15 million per program, significantly lower than the $50 million industry average. However, it must continuously fund high-throughput laboratory operations in Vancouver to generate the data necessary for training its generative AI models.
What could damage it
It faces potential loss of recurring income because no partner has licensed its product candidates for clinical or commercial use as of March 2026.
A critical risk is the inability to transition from technical milestones to commercial licenses. Although it has partnered with leading pharmaceutical companies since 2018, the company has yet to see a partner exercise a license for the clinical use of an AI-designed candidate.
If partners terminate agreements after the discovery phase, the company will fail to realize the downstream royalties and milestones that represent the majority of its potential economic value, leaving it permanently reliant on dilutive financing to fund its internal clinical trials.
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.